Status | Study |
RECRUITING |
Study Name: In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma Condition: Pheochromocytoma Date: 2022-10-20 Interventions: A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery |
RECRUITING |
Study Name: Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) Condition: Pheochromocytoma Date: 2020-10-08 Interventions: measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before a |
RECRUITING |
Study Name: Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Date: 2019-01-31 Interventions: Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.Starting |
Not yet recruiting |
Study Name: Surgeon-Anesthesiologist Collaboration Condition: Pheochromocytoma Collaboration Date: 2017-05-17 Interventions: Procedure: Surgery complications Assessment of the influence of surgeon-anesthesiologist collaboration o |
Temporarily not available |
Study Name: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma Condition: Neuroblastoma Pheochromocytoma Date: 2017-01-05 Interventions: Drug: 131-I-meta-iodobenzylguanidine Other Names: 131I-MIBG Io |
Not yet recruiting |
Study Name: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Condition: Malignant Adrenal Gland Pheochromocytoma Malignant Paragangliom Date: 2016-12-28 Interventions: Other: Laboratory Biomarker Analysis |
Available |
Study Name: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2016-11-08 Interventions: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
Active, not recruiting |
Study Name: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Condition: Paragangliomas Pheochromocytomas Date: 2014-06-04 Interventions: Other: PET-CT |
Active, not recruiting |
Study Name: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2013-10-19 Interventions: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
Withdrawn |
Study Name: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Condition: Phaeochromocytoma Paraganglioma Date: 2013-09-10 Interventions: Drug: Vandetanib 100 mg, 200 m |